23/09/16 – AFABILITY joins the ECVAM Stakeholder Forum (ESTAF)

AFABILITY is pleased to announce that its application to join the European ECVAM Stakeholder Forum (ESTAF) has been approved.

The ESTAF's roles are:

-Advocacy, voicing of stakeholder interests (e.g. economical, societal, sectorial etc.)

-Upstream input on relevance and applicability of proposed test methods and testing strategies

-Communicating new activities, trends, scientific and technical issues; strategic and practical aspects of test method development, optimisation, validation and use.

-Serving as a collaborative platform in view of supporting and participating in joint ESTAF and EURL ECVAM activities

-Commenting on draft EURL ECVAM Recommendations following ESAC Peer Review of Validation Studies

Industrial members

A.I.S.E (The international Association for Soaps, Detergents and Maintenance Products); CEFIC (European Chemical Industry Council); COSMETICS EUROPE; ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals); EFfCI (European Federation for Cosmetic Ingredients); EFPIA (European Federation of Pharmaceutical Industries and Associations); IVTIP (In vitro Testing Industrial Platform); IFRA (International Fragrance Association)

Research associations

ESTIV (European Society for Toxicology in vitro); EUROTOX (Federation of European Toxicologists and European Societies of Toxicology); European Primate Network

Animal Welfare associations (civil society)

ADI (Animal Defenders International); ECEAE (European Coalition to End Animal Experiments); Eurogroup for Animals; Humane Society International /Europe; People for the Ethical Treatment of Animals (PETA) Foundation; European Society for Alternatives to Animal Testing (EUSAAT)

Other stakeholders

ECOPA (European Consensus Platform for Alternatives); NCAEI (National Council for Animal Experimentation Israel); Center for Alternatives to Animal Testing Europe (CAAT Europe)


 SCCS (Scientific Committee on Consumer Safety)

More information can be found here.

No Comments Yet.

Leave a comment